e3D Pharma with the University of New South Wales to research cannabinoid actives for PTSD and Anxiety treatments using translational behavioural models.

Home / Archives for Josh

e3D Pharma with the University of New South Wales to research cannabinoid actives for PTSD and Anxiety treatments using translational behavioural models.

SYDNEY AUSTRALIA – 28th June 2021– e3D Pharma, a subsidiary of CannaPacific, today
announced they have commenced a first of its kind research partnership with the University
of New South Wales using translational models to examine cannabis based actives in the
treatment of PTSD and Anxiety.

Post-Traumatic Stress Disorder (PTSD) is a serious and often chronic mental health
condition that affects around one in every 15 Australians each year (Source: Beyond Blue).
PTSD is more common in women and is a life debilitating illness afflicting 2.1% of people
globally.

e3D Pharma’s highly experienced pharmaceutical development team are producing high
purity actives isolated from in-house developed cannabis strains and together with the
University of New South Wales they are evaluating their pharmacological role in memory
consolidation within the treatment of PTSD with the aim of developing new authorised
medicines.

“In our lab at the University, we investigate a number of different issues related to
behavioural neuroscience. We examine a broad range of topics, including the behavioural
and neural processes involved in fear expression and inhibition, pharmacological adjuncts to
enhance fear loss, and the effects of early life stress on physical and emotional
development. Our overarching aim is to gain a better understanding of learning and memory,
and conduct our research in a way that has potential translational value for understanding
anxiety disorders.” said Prof. Rick Richardson.

“The human endocannabinoid system plays an important role in emotional responses such
as fear and memory. With over 100 years of experience in pharmaceutical development and
manufacturing the team at e3D Pharma are committed to high quality science to fill the
existing gaps in understanding the clinical effectiveness of cannabinoid based medicines.”
said Tim Bowser, e3D Pharma’s Chief Scientific Officer.

“e3D Pharma is proud of the opportunity to work with the University of NSW’s globally
recognised expert team in the Richardson Lab in order to improve the scientific knowledge
base within this important therapy area” said Dr Mike Fay, e3D Pharma’s Chief Medical
Officer.

About e3D Pharma:
e3D Pharma, subsidiary of CannaPacific, is an Australian biotechnology company focused on the
cannabinoid pharmaceutical sector.
Using a traditional approach to drug development, e3D Pharma
seeks to build a global therapeutic offering with an initial focus on palliative care and post traumatic
stress disorder.

About Cannapacific:
CannaPacific is a specialist cultivator of high quality, premium Australian medicinal cannabis
products.
We own our best-in-class cultivation facility. It is located in regional NSW, which has the perfect
climate for cultivation. It is secure, scalable and in the process of gaining GMP certification.

About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and
policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis
products for patients in Australia.https://www.tga.gov.au/medicinal-cannabis-guidance-documents

Contact:
Joshua Dennis (CEO)
josh@cannapacific.com.au
Ph: +61 427 631 61

Novel pain signalling assays for the development of cannabinoid-based medicines

Home / Archives for Josh

Novel pain signalling assays for the development of cannabinoid-based medicines

NEWCASTLE, AUSTRALIA – Friday, 18 Dec  2020 – Australian biotechnology company CannaPacific, today announced they will use novel assays to improve  understanding of cannabinoid-based medicines and their impact on human pain.

CannaPacific’s highly experienced pharmaceutical development team are producing high purity actives isolated from in-house developed cannabis strains. These isolates will then be screened at the University of Newcastle using pain signalling assays to establish new knowledge that will enable the development of improved pain medicines. 

“Attaining insights into the ancient human endocannabinoid system is leading researchers to believe that medicinal cannabis has an untapped role to play in both pain signalling and perception. This will provide CannaPacific with the ability to produce novel cannabinoid product formulations to address the unmet needs in pain management,” said Tim Bowser, the Chief Scientific Officer at CannaPacific.

Dr Erica Cameron-Taylor is a Palliative medicine specialist working with CannaPacific on the development of cannabinoid medications. “Improved medications for acute and chronic neuropathic pain – particularly for patients with cancer and patients in palliative care settings – is one of the Holy Grails of medicine. This research to understand the mechanisms behind how cannabinoids can treat pain is an exciting development for the future of pain management,” said Dr Erica Cameron-Taylor.

Associate Professor Brett Graham’s research at the University of Newcastle is aimed at understanding the complex relationships between pain and spinal cord signalling. “Thankfully, we’re coming into a time when the techniques we can use to study these connections and circuits are rapidly advancing. What we really want to do is identify the different types of sensory nerve cells in the spinal cord, work out how they’re connected and what that means for pain signalling. Along the way, we’ve developed a number of assays that allow us to test if novel compounds can disrupt spinal pain signalling” said Associate Professor Brett Graham.

CannaPacific ensures product quality along the entire supply chain. Extraction and manufacture are performed by Extractas Bioscience (formerly Tasmanian Alkaloids), a leading cGMP medicinal cannabis service provider and a global leader in the production of pharmaceutical ingredients from medicinal plants.

CannaPacific and the University of Newcastle are aiming for a long-term collaborative research partnership, including PhD students who will gain direct experience in the pharmaceutical drug development process.

CannaPacific is licenced & permitted by the Australian Government to cultivate and research medicinal cannabis. This includes an Office of Drug Control location undisclosed approved regional cultivation and research facility in Northern NSW. No cannabis plants are kept on-site at the University of Newcastle.

About CannaPacific:

CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post-traumatic stress disorder.

CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

About medicinal cannabis:

Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents

Human Endocannabinoid System: The human Endocannabinoid System is an ancient neuromodulatory system found in all vertebrates. It plays a role in a wide variety of functions and processes and it is this breadth of effect that results in cannabinoids in medicinal cannabis and having such a wide scope of activity across a multitude of symptoms.

cGMP: refers to Current Good Manufacturing Practice regulations enforced by the TGA. cGMP’s provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities for therapeutic drugs.

Contact:

Joshua R Dennis
josh@cannapacific.com.au
Ph: +61 427 631 611

CannaPacific and CSIRO trial novel encapsulation technologies for medicinal cannabinoids

Home / Archives for Josh

CannaPacific and CSIRO trial novel encapsulation technologies for medicinal cannabinoids

NEWCASTLE, AUSTRALIA, 10 Dec 20 – CannaPacific, an Australian biotechnology company focused on the cannabinoid pharmaceutical sector today announced a partnership with the CSIRO, Australia’s national science agency, to trial novel encapsulation technologies for more effective medicinal cannabinoids.

Current oral medicinal cannabis products have low and inconsistent bioavailability — which refers to the proportion of the medicinal substance absorbed by the body in order to have an active effect — leading to inconsistent therapeutic benefit.

CannaPacific has commenced a proof-of-concept study of the encapsulation technology, developed in collaboration between CSIRO’s Probing Biosystems Future Science Platform and The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN).

Dr Alison White, inventor of the technology and CSIRO-AIBN postdoctoral research fellow said mineral-based thin shells were used to completely surround the cannabinoid with a protective barrier to form a microcapsule.

“This barrier is designed to prevent premature release of the drug, and allows a higher level of control over where and when the drug is released,” Dr White said.

“By controlling the dissolution rate of the microcapsules, we anticipate a more consistent delivery of the cannabinoids into the bloodstream.”

The greater control this technology will provide is anticipated to remedy the current inconsistency of oil-based cannabinoid products. When coupled with optimised formulations of specific cannabinoid medicines, this improved delivery should reduce variability and allow for the preparation of more effective cannabinoid medicines.

“The initial project will be a proof of concept for CSIRO technology when applied to the delivery of cannabinoid-based medicines, and this forms one of a suite of research projects being undertaken by CannaPacific in order to improve the quality of cannabinoid-based medicines” said Tim Bowser, CannaPacific’s Chief Scientific Officer.

CannaPacific aims to be leaders in providing the best in class cannabinoid products, providing prescribers with more certainty around the use of cannabis based products and patients with better outcomes.

With a team highly experienced in translational research on high-value products from medicinal plants, this collaboration will focus on the development of new cannabinoid medicines. This collaboration aligns fully with CannaPacific’s agricultural research, cGMP supply chain, preclinical development and clinical trial programs. CannaPacific is licenced by the Australian Government to cultivate and research medicinal cannabis. This includes an Office of Drug Control location undisclosed approved regional cultivation and research facility in Northern NSW.

About CannaPacific:

CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post-traumatic stress disorder. CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products. CannaPacific operates a full cGMP Medicinal Cannabis Supply Chain which is underpinned by a licenced cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area.

About CSIRO:

CSIRO is Australia’s national science agency and innovation catalyst. We solve the greatest challenges through innovative science and technology. Our collaborative research turns science into solutions for food security and quality; clean energy and resources; health and wellbeing; resilient and valuable environments; innovative industries; and a secure Australia and region.

About AIBN:

The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology (AIBN) is an integrated multi-disciplinary research institute bringing together the skills of world-class researchers in the areas of bioengineering and nanotechnology. AIBN seeks to deliver innovative solutions to society’s problems through sustainable materials, healthy living and translational success. Our research is underpinned by AIBN’s Pillars of Research. These pillars focus AIBN’s research efforts on developing new products, processes and devices for improving human health, the environment and quality of life. In this way, the Institute goes beyond basic research to promote and develop the growth of innovative industries, which will benefit Queensland and Australian economies.

About medicinal cannabis:

Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinalcannabis-guidance-documents

Contact:

Joshua R Dennis
josh@cannapacific.com.au
Ph: +61 427 631 611

CannaPacific Awarded Permits for Cultivation, Production and Research of Medicinal Cannabis

Home / Archives for Josh

CannaPacific Awarded Permits for Cultivation, Production and Research of Medicinal Cannabis

Byron Bay Hinterland, Australia – 02 Dec 20 Australian Biotech company, CannaPacific, today announced the award of permits enabling the commencement of cultivation, production and research of medicinal cannabis plants at their Byron Bay Hinterland facility.

The permits, granted by the Office of Drug Control, is a major step forward for CannaPacific and  represents the culmination of complex planning and hard work.

“The award of these permits is a major achievement for the CannaPacific team. To achieve a permit in this Australian Regulatory environment is extremely difficult and represents several years of extensive planning, construction and substantial investment. We can now fulfill our offtake agreements and expand on our advanced genomic breeding programmes with our partners,” said CEO, Joshua Dennis.

The Northern Rivers facility consists of 10,000 sqm under glass and large outdoor cultivation area protected by the highest level of security.

Under their medical cannabis licence, CannaPacific will produce dried flower for extraction and pharmaceutical production to meet the growing global medicinal cannabis market. The CannaPacific facility also includes a plant research area for variety development in collaboration with R&D partners including the University of Newcastle and Tasmanian Alkaloids.

Cultivation and the development of plant varieties underpins CannaPacific’s strategy by focussing on linking the underlying plant genetics to develop high yielding new cannabis varieties. These new varieties with novel cannabinoid profiles, will be used to support our pharmaceutical development program on pure cannabinoid based medicines.

CannaPacific is licenced and permitted by the Australian Government to cultivate and research medicinal cannabis in an undisclosed location in Northern NSW. 

——————————————————————————————————————————–

About CannaPacific:
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post traumatic stress disorder.

CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

CannaPacific operates a cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area.

About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents

Contact:
Joshua Dennis (CEO)
josh@cannapacific.com.au
Ph: +61 427 631 611

 

CannaPacific Collaborates with Greening Australia for Bushfire Regeneration

Home / Archives for Josh

CannaPacific Collaborates with Greening Australia for Bushfire Regeneration

LISMORE, AUSTRALIA – 15 October 2020 – Lismore-based CannaPacific, a biopharmaceutical company focused on medicinal cannabis, announced today an initiative to grow and donate 60,000 tube stock native plants annually for local regeneration projects in their cultivation and research facility near Lismore. This project is supported by environmental enterprise, Greening Australia, who will be providing native seed to the initiative.

Joshua Dennis, CEO of CannaPacific, has forged a strong relationship with Greening Australia with an aspiration to become a part of restoration efforts in Australia. “We share the enthusiasm of Greening Australia, the Australian government and the broader community in wanting to see the regeneration of our unique native forests, and the restoration of the natural habitat for our native animals and birds.

CannaPacific’s agreement with Greening Australia will enable us to contribute through growing and maintaining approximately 60,000 native tube stock plants annually to an advanced stage of growth on our Lismore property. Once the trees are ready to be placed in local projects, this would produce plantings equivalent in size to 2500 football fields per year. That’s a real win for the environment.” said Joshua Dennis today.

In the wake of the horrific fires that devastated the Australian landscape, Greening Australia with expertise in the seed space, were appointed by the Federal Government to lead the development of a strategic program to build and secure native seed and plant supply for landscape restoration.

Commenting on the recent events of horrendous bushfires, distressing scenes of native animals struggling to survive, and the current pandemic, Joshua said “Those events have been truly terrible. It’s a fragile world that we live in. We see plants in the ground as a big part of the solution in helping our native flora and fauna to regenerate and to stop erosion.”

——————————————————————————————————————————–

About CannaPacific:
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post-traumatic stress disorder.

CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

CannaPacific operates a cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area.


About Greening Australia:
Greening Australia has been restoring and conserving Australia’s unique landscapes at scale through collaborative, science-based and innovative programs for over 38 years. Greening Australia is committed to tackling Australia’s greatest environmental challenges in ways that work for communities, economies and nature; planting millions of native trees and plants, protecting hundreds of native species, and supporting Traditional Owners aspirations for restoring country.  For more information, visit  www.greeningaustralia.org.au


Contact:
Emily Bowser (Media Relations)
emily@cannapacific.com.au
Ph: +61 419 303 313

First Australian Export of Cannabis Product to South Africa

Home / Archives for Josh

First Australian Export of Cannabis Product to South Africa

NEWCASTLE, AUSTRALIA – Tuesday 22 September 2020 – CannaPacific, an Australian biotechnology company focused on the cannabinoid pharmaceutical sector and Health House International have joined forces to be the first Australian companies to export medicinal cannabis products to South Africa successfully.

Utilising CannaPacific’s supply chain and Health House International’s import/export expertise, these leading Australian medicinal cannabis companies have led the way to open up this complex supply chain. Regulations surrounding inter-country movement of medicinal cannabis products are still evolving. Opening up the supply of export approved products for CannaPacific is a significant step forward for the Australian Industry.

“It’s great to see Australian companies working together to build an export supply chain for medicinal cannabis products and competing on a global scale,” said CannaPacific CEO, Josh Dennis.

Pharmacist and Health House International COO Paul Mavor, the first licensed importer of Canadian medicinal cannabis in May 2017, said “This shipment is the first export of Australian cannabis to Africa. It is a really significant step in cementing Australia’s place as a global supplier of pharmaceutical-grade medicinal cannabis. Projections are for Australian medical patients to hit 300,000 over the next few years, and the export market offers huge potential.”

About CannaPacific:
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post-traumatic stress disorder.

CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

CannaPacific operates a full cGMP Medicinal Cannabis Supply Chain which is underpinned by a licenced cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area. 

About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents

Contact:

Emily Bowser (Media Relations)
emily@cannapacific.com.au
Ph: +61 419 303 313

CannaPacific and the University of Newcastle join forces to progress an advanced medicinal cannabis breeding program.

Home / Archives for Josh

CannaPacific and the University of Newcastle join forces to progress an advanced medicinal cannabis breeding program

NEWCASTLE, AUSTRALIA – Monday, 14 Sept 2020 – Australian biotechnology company CannaPacific along with the University of Newcastle and Xing Technologies, today announced they are working together to develop one of the most advanced medical cannabis genomic breeding programs in the world.

With a team highly experienced in translational research on high-value products from medicinal plants, the collaboration will focus on novel traits of cannabis plants, applying cutting edge techniques to engineer novel medicinal cannabis varieties, driving reduced variability, and increasing productivity.

Through the development of genetic markers, we can identify specific parts of the plant genome that are significant, and select which plants to incorporate into our breeding program in order to combine desirable traits such as specific cannabinoid profiles and yield, and track these markers through subsequent generations,” said Professor Christopher Grof, Director of the University of Newcastle’s Centre for Plant Science. 

“This will provide CannaPacific with the ability to produce cultivars that accumulate the desired cannabinoid content to support the development of new medicinal cannabis treatments and novel cannabinoid product formulations,” said Tim Bowser, the Chief Scientific Officer at CannaPacific.

Through a collaboration with the biotechnology company Xing Technologies, the team have the ability to fast track the identification of molecular markers which when coupled to CannaPacific’s broad selection of genetically diverse medicinal cannabis varieties, will drive the development of new low-cost formulations for the improved delivery of medicinal cannabis products.

CannaPacific ensures product quality along the entire supply chain, extraction and manufacture are performed by Tasmanian Alkaloids, a leading cGMP medicinal cannabis service provider and a global leader in the production of pharmaceutical ingredients from medicinal plants.

CannaPacific also has a research collaboration in place with Tasmanian Alkaloids, a global leader in research on medicinal plant extracts, allowing the team to access a substantial stock of genetic material.

CannaPacific and the University of Newcastle are aiming for a long-term collaborative research partnership, including PhD students who will experience the future of plant science whilst embedded within both CannaPacific and Xing Technologies.

CannaPacific is licenced by the Australian Government to cultivate and research medicinal cannabis. This includes an Office of Drug Control location undisclosed approved regional cultivation and research facility in Northern NSW. No cannabis plants are kept on-site at the University of Newcastle.

QUOTES:

“CannaPacific’s scientific program working with global industry technology leaders combines advanced genomic and molecular breeding technologies to advance the development of novel cannabinoid medicines,” Tim Bowser, Chief Scientific Officer for CannaPacific

——————————————————————————————————————————–

About CannaPacific:
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post traumatic stress disorder.

CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

CannaPacific operates a cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area.

About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents

Contact:
Joshua Dennis (CEO)
josh@cannapacific.com.au
Ph: +61 427 631 61

Medicinal cannabis company CannaPacific officially opens its head office in Dudley on Wednesday

Joshua_Dennis

[et_pb_section fb_built=”1″ _builder_version=”4.0.11″][et_pb_row _builder_version=”4.0.11″][et_pb_column type=”4_4″ _builder_version=”4.0.11″][et_pb_image src=”https://cannapacific.com.au/wp-content/uploads/2020/02/IMG_9965-scaled.jpg” _builder_version=”4.0.11″][/et_pb_image][et_pb_text _builder_version=”4.0.11″]A MEDICINAL cannabis company opening in the Hunter hopes to ease the uncertainty of GPs who have been disinclined to prescribe the drug to date.

View Full Article
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Cannapacific Is Pleased To Welcome Tim Bowser

Home / Archives for Josh

Cannapacific Is Pleased To Welcome Tim Bowser

14 November 2019 – CannaPacific is pleased to announce the appointment of Tim Bowser as Chief Scientific Officer. Tim heads up the scientific operations of CannaPacific, drawing experience from his recent role as the Head of Australian Operations and R&D for Sun Pharmaceutical Industries – Australia’s Controlled Substances Division.

With over 35 years experience in the pharmaceutical industry, and 25 years in controlled substances  as Site Director for Sun Pharma’s Controlled Substances as well as in Business Development, Operations and Quality, Tim is highly experienced in genomic-based molecular breeding of medicinal plants for the production of pharmaceutical actives.

Tim’s professional qualifications include a Bachelor of Applied Science (Chemistry) from Central Queensland University; Master of Science Qualifier – Natural Products at Deakin University; and an Honorary Fellow from the University of Melbourne. 

During his career Tim has led a major capital expansion program of over A$70million including a Fine Chemicals manufacturing plant (Finalist Australian Engineering Excellence Awards) and A$20million Natural product extraction facility. 

Tim recently completed a stint as an Industrial Placement Fellow at the University of York overseeing a range of new technology projects applying Molecular biology and genetics to plant breeding for High Value Chemicals from Plants, large scale extraction technology as well as applications of Industrial Biotechnology in pharmaceutical actives manufacture.

————————————————————————————————————————————————————

About CannaPacific:
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post traumatic stress disorder.

CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents

Contact:
Joshua Dennis (CEO
josh@cannapacific.com.au
Ph: 0427 631 611 

CannaPacific Welcomes Dr Michael Fay As Chief Medical Officer

Home / Archives for Josh

CannaPacific Welcomes Dr Michael Fay As Chief Medical Officer

15 October 2019 – CannaPacific is pleased to announce the appointment of Dr Mike Fay to our team as our Chief Medical Officer. This extends his current role as an Executive Director. Mike brings  impeccable credentials as the Chief Medical Officer, strengthening CannaPacific’s medical and product development team.

Mike completed his undergraduate degree of Medicine and Surgery at University of Otago 1993 and is currently completing his PhD on integrating advanced imagery into brain tumour treatment.

Conducting extensive research with a particular focus on brain tumours and the development of new imaging and treatment techniques, Mike is the principal investigator in a number of international cancer trials and collaborations with Canada, the UK and Germany. His research spans across several modalities including PET imagery, MRI imaging and developing multiplexed neuro-imaging techniques. Mike is a lead researcher in an NCIC trial into brain tumour treatment in elderly patients. A current research project centres on developing a new PET tracer for use in brain tumours.

Publishing extensively on both lung and neuro-oncology and alongside his commitment to research, Mike is a Senior Lecturer at the University of Queensland and a Conjoint Senior Lecturer at the University of Newcastle. He is also an active member of ASCO, ASTRO and COGNO and on the editorial board of The Journal of Translational Lung Cancer Research.

————————————————————————————————————————————————————

About CannaPacific:
CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post traumatic stress disorder.

CannaPacific’s strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

About medicinal cannabis:
Governments at both Commonwealth and State and Territory levels have implemented legislative and policy change to allow the cultivation, manufacture, prescribing and dispensing of medicinal cannabis products for patients in Australia. https://www.tga.gov.au/medicinal-cannabis-guidance-documents

Contact:
Joshua Dennis (CEO)
josh@cannapacific.com.au
Ph: 0427 631 611

Tim heads up the scientific operations of CannaPacific drawing experience from his recent role as the Head of Australian Operations and R&D for Sun Pharmaceutical Industries Australia’s Controlled Substances Division.

With over 35 years experience in the pharmaceutical industry, and 25 years in controlled substances  as Site Director for Sun Pharma’s Controlled Substances as well as in Business Development, Operations and Quality, Tim is highly experienced in genomic-based molecular breeding of medicinal plants for the production of pharmaceutical actives

Tim’s professional qualifications include a Bachelor of Applied Science (Chemistry) from Central Queensland University; Master of Science Qualifier – Natural Products at Deakin University; and was made an Honorary Fellow from the University of Melbourne. 

During his career Tim has led a major capital expansion program of over A$70million including a Fine Chemicals manufacturing plant (Finalist Australian Engineering Excellence Awards) and A$20million Natural product extraction facility. 

Tim recently completed a stint as an Industrial Placement Fellow at the University of York overseeing a range of new technology projects applying Molecular biology and genetics to plant breeding for High Value Chemicals from Plants, large scale extraction technology as well as applications of Industrial Biotechnology in pharmaceutical actives manufacture.

————————————————————————————————————————————————————

About CannaPacific:
CannaPacific is an Australian biotech company focused on the cannabinoid pharmaceutical sector. Licenced by the Australian Government to cultivate and research medicinal cannabis, CannaPacific has acquired an amazing 10,000 sqm Dutch glasshouse near Byron Bay, NSW to optimise the cultivation of medical cannabis to GACP & GMP Standards.

Contact:
Joshua Dennis
CEO
+61 427 631 611
josh@cannapacific.com.au